Visão geral da empresa
A clinical-stage biotechnology enterprise, Recursion Pharmaceuticals, Inc. is dedicated to the process of decoding biology and chemistry through the integration of technological innovations spanning biology, chemistry, automation, data science, and engineering to industrialize drug discovery within the United States and the United Kingdom. The company operates within the Healthcare sector, specifically the Biotechnology industry, which typically involves high-risk, high-reward development of novel therapeutics before they reach market approval. As of the latest reporting period, the firm holds a market capitalization of $1.79B and generated annual revenue of $74.68M, employing a workforce of 600 individuals. These valuation and revenue figures indicate that the company maintains a significant market presence relative to its current operational scale, yet the revenue level suggests it is still in a phase of scaling operations rather than mature commercialization. The substantial market cap relative to the current annual revenue highlights the market's valuation of the company's pipeline and technological assets over current cash flow generation.
Saúde financeira
The company reported revenue of $74.68M for the trailing twelve months, accompanied by a net income of -$644,758,976 and an EBITDA of -$564,430,976. The substantial gap between the positive revenue of $74.68M and the deeply negative net income reveals a cost structure where operational expenses, likely driven by research and development and engineering costs, far exceed the revenue generated, which is typical for clinical-stage biotechnology firms. Free cash flow stands at -$208,521,744, indicating that the company is currently burning cash to fund its growth initiatives rather than generating surplus liquidity. This negative free cash flow implies limited financial flexibility for the immediate future, relying heavily on external capital markets or existing cash reserves to sustain operations. The margin profile presents a stark reality: the gross margin is 0.0%, the operating margin is -328.8%, and the profit margin is 0.0%, collectively indicating that the company has not yet achieved profitability at the gross or operating level and is losing money on a significant scale relative to sales. In terms of solvency, the company holds $743.29M in cash against total debt of $77.97M, resulting in a debt-to-equity ratio of 6.89, which suggests a highly leveraged balance sheet structure despite the low absolute debt figure. Furthermore, the current ratio of 5.50 indicates strong short-term liquidity, as current assets are more than five times current liabilities, providing a buffer to meet obligations. However, the return on equity is -59.5% and the return on assets is -27.7%, metrics that reveal management has yet to generate positive returns on the capital invested by shareholders or utilized in asset operations.
Avaliação de valorização
The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is -3.98, a metric that implies negative earnings expectations for the upcoming period. The disparity between a non-existent trailing P/E and a negative forward P/E suggests that the market is pricing in continued earnings losses rather than expecting immediate profitability in the near term. The price-to-book ratio stands at 1.58, indicating that the market values the company at 1.58 times its book value, which suggests a premium over the net asset value despite the company's unprofitable status. Alternative valuation metrics such as the price-to-sales ratio of 23.98 and the EV/EBITDA of -1.99 further illustrate that the stock is priced on future growth potential rather than current earnings power or cash flow generation. Regarding price volatility, the stock traded with a 52-week high of $7.18 and a 52-week low of $2.80. Assuming the current price is near the lower end of this range based on typical reporting contexts for such firms, the stock is trading significantly below its recent peak, reflecting the challenges faced by clinical-stage entities. The beta of 1.01 indicates that the stock's price volatility is generally in line with the broader market, suggesting it does not exhibit extreme sensitivity to overall market swings like high-beta biotech stocks often do.
Growth & Income
Revenue growth year-over-year is recorded at an impressive 681.7%, reflecting a massive expansion in top-line activity, likely due to new product launches, strategic acquisitions, or the commercialization of previous clinical assets. Earnings growth is listed as N/A given the persistent negative net income, meaning that while revenue is expanding rapidly, the company has not yet achieved positive earnings to measure growth in profitability terms. Consequently, the expansion in revenue is occurring without a corresponding improvement in earnings, which is characteristic of companies reinvesting heavily in research before reaching profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash and generated revenue are being reinvested into growth initiatives rather than distributed to shareholders. This reinvestment strategy is essential for a clinical-stage biotechnology company to fund its drug discovery pipeline and technological infrastructure. The overall growth and income profile is defined by aggressive revenue expansion coupled with significant cash burn, offering potential for future commercial success but presenting immediate liquidity challenges for investors monitoring cash reserves.